Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.

abstract：:High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We p...

journal_title：Bone marrow transplantation

authors： Thieblemont C,Dumontet C,Saad H,Roch N,Bouafia F,Arnaud P,Hequet O,Espinouse D,Salles G,Roy P,Eljaafari-Corbin A,Du Manoir-Baumgarten C,Coiffier B

更新日期：2002-12-01 00:00:00

abstract：:Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

更新日期：2007-10-01 00:00:00

abstract：:To augment graft cell dose, we evaluated the safety of the combined transplantation of two partially HLA-matched umbilical cord blood (UCB) units. Five patients with transfusion-dependent thalassemia, median age 11.1 years (range 10-13.1), received 2 UCB units after myeloablative conditioning. Cord blood units were a ...

journal_title：Bone marrow transplantation

authors： Jaing TH,Yang CP,Hung IJ,Chen SH,Sun CF,Chow R

更新日期：2007-08-01 00:00:00

abstract：:Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the...

journal_title：Bone marrow transplantation

authors： Liao Y,Cotten M,Tan S,Kurtzberg J,Cairo MS

更新日期：2013-07-01 00:00:00

abstract：:ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored ...

journal_title：Bone marrow transplantation

authors： Heal JM,Liesveld JL,Phillips GL,Blumberg N

更新日期：2005-11-01 00:00:00

abstract：:On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic ...

journal_title：Bone marrow transplantation

authors： Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

更新日期：2019-11-01 00:00:00

abstract：:The majority of adult patients have sexual concerns after post-haematopoietic cell transplantation. Even so, health-care professionals (HCP) do not routinely discuss these problems. We, therefore, surveyed all the members of the European Society for Blood and Marrow Transplantation to evaluate the barriers and facilit...

journal_title：Bone marrow transplantation

authors： Eeltink CM,Witte BI,Stringer J,Liptrott S,Babic A,Greenfield DM,Salooja N,Incrocci L,Visser O,Verdonck-de Leeuw IM,Duarte RF,Zweegman S

更新日期：2018-03-01 00:00:00

abstract：:We investigated the nature of hemostatic alterations occurring after bone marrow transplantation. In 45 patients, we evaluated the coagulation parameters, naturally occurring anticoagulants and thrombomodulin at days +15 and +22 after conditioning therapy. It was observed that endothelial cell damage is a central path...

journal_title：Bone marrow transplantation

authors： Testa S,Manna A,Porcellini A,Maffi F,Morstabilini G,Denti N,Macchi S,Rosti G,Porcellini G,Cassi D,Ferrari L

更新日期：1996-08-01 00:00:00

abstract：:We have tested the immunologic status and hematologic parameters of mice 2 months (short-term survivors) or 18 months (long-term survivors) after lethal total body irradiation and syngeneic bone marrow transplantation (SBMT), and of normal mice of corresponding age. Long-term SBMT survivors showed significantly lowere...

journal_title：Bone marrow transplantation

authors： Skórski T,Kawalec M,Ratajczak M,Szczylik C,Kawiak J

更新日期：1990-11-01 00:00:00

abstract：:Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

journal_title：Bone marrow transplantation

authors： Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

更新日期：1998-10-01 00:00:00

abstract：:Up to now there are no data on long-term effects of allogeneic peripheral blood cell transplantation (AlloPBPCT). In particular, long term effects on healthy donors by the mobilization procedure which includes the exposition to G-CSF over several days are unknown. Recently the possibility of an increase in risk for ac...

journal_title：Bone marrow transplantation

authors： Hasenclever D,Sextro M

更新日期：1996-03-01 00:00:00

abstract：:Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

journal_title：Bone marrow transplantation

authors： Heying R,Nürnberger W,Spiekerkötter U,Göbel U

更新日期：1998-05-01 00:00:00

abstract：:Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...

journal_title：Bone marrow transplantation

authors： Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

更新日期：2000-09-01 00:00:00

abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

journal_title：Bone marrow transplantation

authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

更新日期：2020-10-01 00:00:00

abstract：:Ovarian failure after allogeneic stem cell transplant (allo-SCT) is an important risk factor for development of osteoporosis. We investigated the effects of various antiresorptive treatments in long-term surviving females with ovarian failure after allo-SCT. A total of 60 women with osteoporosis or osteopenia were div...

journal_title：Bone marrow transplantation

authors： Tauchmanovà L,De Simone G,Musella T,Orio F,Ricci P,Nappi C,Lombardi G,Colao A,Rotoli B,Selleri C

更新日期：2006-01-01 00:00:00

abstract：:Forty-eight adult patients with recurrent or refractory intermediate grade or immunoblastic lymphoma received high-dose carmustine (BCNU), etoposide, Ara C and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (BMT). Median follow-up is 906 days (range 613-2067 days). The complete remission r...

journal_title：Bone marrow transplantation

authors： van Besien K,Tabocoff J,Rodriguez M,Andersson B,Mehra R,Przepiorka D,Dimopoulos M,Giralt S,Suki S,Khouri I

更新日期：1995-04-01 00:00:00

abstract：:The purpose of this study was two-fold: to describe the quality of life and behavioral adjustment of survivors of pediatric bone marrow transplantation (BMT) prior to and 6 months post-BMT; and, to identify correlates of survivors' quality of life and behavioral adjustment. Participants were 26 children and adolescent...

journal_title：Bone marrow transplantation

authors： Barrera M,Boyd-Pringle LA,Sumbler K,Saunders F

更新日期：2000-08-01 00:00:00

abstract：:Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the ou...

journal_title：Bone marrow transplantation

authors： Cahu X,Chevallier P,Clavert A,Suarez F,Michallet M,Vincent L,Vigouroux S,Blaise D,Mariette C,Bilger K,Robin M,Yakoub-Agha I,Peffault de Latour R,Mohty M

更新日期：2014-06-01 00:00:00

abstract：:Approaches to determine whether one transplant-related therapy is better than another include: (1) using experimental data, such as those from randomized controlled trials (RCTs); (2) using observational data, such as those from observational databases (ODBs) and (3) using conclusions from the structured quantificatio...

journal_title：Bone marrow transplantation

authors： Gale RP,Eapen M,Logan B,Zhang MJ,Lazarus HM

更新日期：2009-03-01 00:00:00

abstract：:Respiratory syncytial virus (RSV), a common cause of both upper and lower respiratory tract infection (LRTI) in infants and children, is rarely described as an infective agent in adults. It has been reported in bone marrow transplant (BMT) recipients and patients with malignancy immunosuppressed by chemotherapy. Such ...

journal_title：Bone marrow transplantation

authors： McColl MD,Corser RB,Bremner J,Chopra R

更新日期：1998-02-01 00:00:00

abstract：:We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous leukemia patients who underwent allogeneic blood or marrow transplantation (allotx). In all, 47 patients received intravenous (i.v.) busulfan and cyclophosphamide (i.v...

journal_title：Bone marrow transplantation

authors： Thall PF,Champlin RE,Andersson BS

更新日期：2004-06-01 00:00:00

abstract：:The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

journal_title：Bone marrow transplantation

authors： Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

更新日期：1999-12-01 00:00:00

abstract：:Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that furth...

journal_title：Bone marrow transplantation

authors： Oyama Y,Traynor AE,Barr W,Burt RK

更新日期：2003-08-01 00:00:00

abstract：:Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a mor...

journal_title：Bone marrow transplantation

authors： Kiehl MG,Shipkova M,Basara N,Blau WI,Fauser AA

更新日期：2000-05-01 00:00:00

abstract：:ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

journal_title：Bone marrow transplantation

authors： Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

更新日期：2004-08-01 00:00:00

abstract：:In this cross-sectional study, we compared the quality of life (QOL) in transfusion-dependent thalassemic patients who survived matched sibling hematopoietic SCT (HSCT, n=24) with patients treated conventionally with transfusion and iron chelation (n=74). WHOQOL-BREF(HK) and PedsQL questionnaires were administered to ...

journal_title：Bone marrow transplantation

authors： Cheuk DK,Mok AS,Lee AC,Chiang AK,Ha SY,Lau YL,Chan GC

更新日期：2008-09-01 00:00:00

abstract：:The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

journal_title：Bone marrow transplantation

authors： Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

更新日期：2013-11-01 00:00:00

abstract：:We describe the case of a HBsAg+, HBeAg+ carrier, treated with lamivudine, who experienced exacerbation of hepatitis after BMT from an anti-HBs+, anti-HBc+, anti-HBe+ donor. The serological profile of the donor and the timing of exacerbation suggested that the adoptive immunity transfer played a major pathogenetic rol...

journal_title：Bone marrow transplantation

authors： Favre C,Menconi MC,Nardi M,Casazza G,Oliveri F,Macchia P,Bonino F,Brunetto MR

更新日期：2004-05-01 00:00:00

abstract：:The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points...

journal_title：Bone marrow transplantation

authors： Montagna D,Locatelli F,Calcaterra V,Comoli P,Moretta A,Giorgiani G,Zecca M,Bonetti F,Giraldi E,Rondini G,Maccario R

更新日期：1998-10-01 00:00:00

abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

journal_title：Bone marrow transplantation

authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

更新日期：1990-01-01 00:00:00